Taysha Gene Therapies, INC. (TSHA) — 10-Q Filings

All 10-Q filings from Taysha Gene Therapies, INC.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (5)

Taysha Gene Therapies' Net Loss Widens Amid Increased R&D Spend — Aug 12, 2025 Risk: high
Taysha Gene Therapies, Inc. (TSHA) reported a net loss of $26.88 million for the three months ended June 30, 2025, an increase from a net loss of $20.93 million
Taysha Gene Therapies Files Q1 2025 10-Q — May 15, 2025 Risk: medium
Taysha Gene Therapies, Inc. filed its 10-Q for the period ending March 31, 2025. The company's fiscal year ends on December 31. Key dates mentioned include Apri
Taysha Gene Therapies Files Q3 2024 10-Q — Nov 13, 2024 Risk: medium
Taysha Gene Therapies, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the th
Taysha Gene Therapies Files Q2 2024 10-Q — Aug 12, 2024 Risk: medium
Taysha Gene Therapies, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business oper
Taysha Gene Therapies Q1 2024 Update — May 14, 2024 Risk: medium
Taysha Gene Therapies, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported cash and cash equivalents of $129.5 million as of March 31

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX